The administrative core will provide essenfial support for all administrafive activities associated with the program project grant^or al| Project and Cores. The administrafive core will provide support for accounting, budgefing, fiscal reporting, protocol submission, dissemination of information between program sites, as well as preparafion and distribution of protocol revisions and yeariy renewal reporting. Protocol monitoring, data coordination, and communicafion among project and core key personnel through in-perSon meefings, regulariy scheduled conference calls, and additional telephone communication will be the responsibility of the administrafive core. Additionally, the core will support scheduling and coordination of internal research meefings and external consultant visits. The Core with centrally coordinate sample and clinical materials distribufion between Projects, participating clinical sites and Cores. The Core will also support clinical trials by coordinafion of research nurse support at the University site for the therapeijitic trials in Projects 2 and 3 and the prospective trials in Project 3.

Public Health Relevance

The administrafive and clinical support core will funcfion to make the group cohesive ahd integrated. This will be accomplished by promofing communication, external review ofthe program, central data collecfion and i safety monitoring and sample disseminafion.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA111412-06
Application #
8001175
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Project Start
2010-08-01
Project End
2015-07-31
Budget Start
2010-09-01
Budget End
2011-07-31
Support Year
6
Fiscal Year
2010
Total Cost
$161,134
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Cooley, Sarah; Parham, Peter; Miller, Jeffrey S (2018) Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood 131:1053-1062
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Oh, Felix; Todhunter, Deborah; Taras, Elizabeth et al. (2018) Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol 10:113-121
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494

Showing the most recent 10 out of 108 publications